Phase II study of FOLFIRI+biweekly cetuximab for KRAS wild type unresectable colorectal cancer.
Ontology highlight
ABSTRACT: Primary outcome(s): Response rate
DISEASE(S): Unresectable Colorectal Cancer
PROVIDER: 2626735 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA